Merck's immuno-oncology star wins fast U.K. nod; Aeterna Zentaris raises $37M;

@FierceBiotech: From @FiercePharmAsia: Glaxo plants a flag in Singapore with CEO Witty on hand. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Amgen is canning 300 Onyx staffers, abandoning campus in latest biopharma purge. News | Follow @JohnCFierce

@DamianFierce: $PTX is buying the rights to $ZGNX's opioid Zohydro ER for $100M up front and up to $283.5M more. Release | FiercePharma story | Follow @DamianFierce

> Merck's ($MRK) PD-1-blocking immunotherapy Keytruda won an early U.K. approval, becoming the first treatment to take advantage of a new accelerated review process in the country. News

> Zogenix ($ZGNX) sold off the rights to its controversial painkiller Zohydro to Pernix Therapeutics ($PTX) for $100 million up front and up to $283.5 million in milestones. More

> Aeterna Zentaris ($AEZS) raised $37 million in a stock offering, money earmarked for its pipeline of cancer treatments. Release

Medical Device News

@FierceMedDev: J&J hosts developer of novel skin cancer diagnostic at its new life science incubator. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Texas Medical Center adds 20+ device companies to its incubator. Story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's edition of FierceDiagnostics, feat. OpGen's superbug Dx, new coverage decisions for $EXAS and more. Newsletter | Follow @EmilyWFierce

> Med tech moves in on Georgia: Varian, MiMedix to expand with up to 250 new jobs. Story

> J&J's DePuy Synthes recalls orthopedic surgical tool, but not ready to replace. News

> Olympus asked FDA to loosen its belt on cleaning guidelines for endoscope devices. Article

Pharma News

@FiercePharma: Stats, surprises and secrets revealed in annual drug-spending report. Story | Follow @FiercePharma

@EricPFierce: #FDA finds sends a warning letter to a second Novacyl API plant for retesting failed batches. News | Follow @EricPFierce

@CarlyHFierce: UPDATED: Just where does AbbVie expect to find $7B in Imbruvica sales? Article | Follow @CarlyHFierce

> Merck's Keytruda snags inaugural approval in U.K.'s early-access scheme. Story

> J&J pleads guilty, pays $20M fine tied to metal-tainted Children's Tylenol. News

Drug Delivery News

> Zohydro changes hands as Zogenix sells to Pernix for $100M-plus. More

> J&J partner Halozyme joins daratumumab trials with delivery tech in tow. Story

> Irish research center wins EU funding to study and develop transdermal delivery methods. News

> Will the third licensee of a buccal tablet for mouth fungus succeed where others have failed? More

> Developer of injectable osteoarthritis treatment postpones $75M IPO, raises $4M in debt instead. Article

Diagnostics News

> Philips, UC Irvine collaborate on diagnosing breast cancer among women with dense breasts. Story

> Exact Sciences signs on Anthem and Aetna to noninvasive colon cancer Dx. Report

> Quest and Personalis dive into exome sequencing for rare pediatric neurological disorders. Editor's corner

> J&J hosts developer of novel skin cancer diagnostic at its new life science incubator in Silicon Valley. More

> Navidea joins forces with Norgine to market cancer imaging Dx in EU. Article

Pharma Marketing News

> Lipitor keeps on selling, so Pfizer will keep on producing it in Ireland. Item

> Just where does AbbVie expect to find $7B in Imbruvica sales? Story

> Stats, surprises and secrets revealed in annual drug-spending report. More

> Onyx field reps spared in Amgen's 300-job bloodletting. Article

> Bayer puts cancer-fighting country crooner onstage to promote colonoscopies. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.